

**What should be the default SFA strategy :
Updated evidence for TASC C or D
femoropopliteal lesions.**

Donghoon Choi

**Cardiology Division, Severance Cardiovascular Hospital,
Yonsei University College of Medicine**

Endovascular treatment in TASC C/D FP lesions?

Revascularization in Patients with FP Lesions

TASC Lesion Classification

| Femoropopliteal lesions | |
|-------------------------|--|
| Lesion type | Description |
| Type A | - Single stenosis ≤ 10 cm in length - Single occlusion ≤ 5 cm in length |
| Type B | - Multiple lesions (stenoses or occlusions), each ≤ 5 cm - Single stenosis or occlusion ≤ 15 cm not involving the infra geniculate popliteal artery - Single or multiple lesions in the absence of continuous tibial vessels to improve inflow for a distal bypass - Heavily calcified occlusion ≤ 5 cm in length - Single popliteal stenosis |
| Type C | - Multiple stenoses or occlusions totaling > 15 cm with or without heavy calcifications - Recurrent stenoses or occlusions that need treatment after two endovascular interventions |
| Type D | - Chronic total occlusion of CFA or SFA (> 20 cm, involving the popliteal artery) - Chronic total occlusion of popliteal artery and proximal trifurcation vessels |

| Recommendations | Class ^a | Level ^b |
|--|--------------------|--------------------|
| When revascularization is indicated, an endovascular-first strategy is recommended in all femoropopliteal TASC A–C lesions. | I | C |
| Primary stent implantation should be considered in femoropopliteal TASC B lesions. | IIa | A |
| A primary endovascular approach may also be considered in TASC D lesions in patients with severe comorbidities and the availability of an experienced interventionist. | IIb | C |

Considerations
 Clinical symptom
 Calcification
 Previous treatment
 Vascular access
 Status of runoff vessels
 Comorbidities

TASC, TransAtlantic Inter-Society Consensus

ESC Guideline, Eur Heart J 2011

Except very long or extended to popliteal artery, FP lesions could be considered as a proper candidate for endovascular intervention

Endovascular interventions for TASC II D femoropopliteal lesions

Donald T. Baril, MD, Rabih A. Chaer, MD, Robert Y. Rhee, MD, Michel S. Makaroun, MD, and Luke K. Marone, MD, *Pittsburgh, Penn*




Fig 2. Survival curve analysis demonstrating primary patency following endovascular intervention.




Fig 3. Survival curve analysis demonstrating assisted-primary patency following endovascular intervention.




Fig 4. Survival curve analysis demonstrating secondary patency following endovascular intervention.


Technical success: 89%

Conclusion: Endovascular intervention can be safely performed with excellent hemodynamic improvement and limb salvage rates




J Vasc Surg 2010;51:1406-12.



Approaching strategies for FP procedure



Subintimal angioplasty





Intraluminal wiring: failed



Subintimal tracking

Almost there, but failed

Recanalization 1) Reentry device




Recanalization 2) Retrograde approach with or without CART / reverse CART



Improved Technical Success and Midterm Patency With Subintimal Angioplasty Compared to Intraluminal Angioplasty in Long Femoropopliteal Occlusions


Young-Guk Ko, MD; Jung-Sun Kim, MD; Dong-Hoon Choi, MD, PhD; Yangsoo Jang, MD, PhD; and Won-Heum Shim, MD, PhD



Outcomes of Subintimal angioplasty


- 2004 - 2011
- 172 SFA of 150 patients
- Mean lesion length: 22.6 ± 8.5 cm
- TASC II B 11%, C or D 89%

- **Primary patency:**
77% at 1 year, 59% at 3 year



| | Follow-up duration (yr) | | | | | |
|----------------|-------------------------|----|----|----|----|----|
| Number at risk | 0 | 1 | 2 | 3 | 4 | 5 |
| Without CLI | 101 | 50 | 50 | 35 | 19 | 15 |
| With CLI | 60 | 27 | 15 | 8 | 6 | 4 |


- **Absence of TLR:**
84% at 1 year, 72% at 3 year



| | Follow-up duration (yr) | | | | | |
|----------------|-------------------------|----|----|----|----|----|
| Number at risk | 0 | 1 | 2 | 3 | 4 | 5 |
| Without CLI | 101 | 67 | 52 | 39 | 23 | 18 |
| With CLI | 60 | 26 | 16 | 9 | 6 | 4 |



Current Options for Endovascular Treatment of Femoropopliteal Lesions

Shishehbor MH, JACC 2015




Usually, stent approach is a good option for TASC C/D lesions, but the alternatives are also available

Supera self-expandable stent



Better option for severe calcified lesion

Directional Atherectomy








Directional Atherectomy + Adjuvant ballooning





Adjuvant ballooning using 5*80 mm balloon

~30% R/S with mild dissection, acceptable result

Jetstream atherectomy



Jetstream atherectomy + DCB



Summary

- **Endovascular treatment in TASC C/D FP lesions**
usually technically feasible, but not ensure long-term patency
- **Subintimal angioplasty**
Reentry device or bidirectional wiring will improve success rate
- **Stent vs “leave nothing behind” approach**
Debulking devices and DCB may reduce the need of stents even in TASC C/D lesions.